'Buying opportunity ahead of growth acceleration' - RBC raises DiaSorin to 'outperform'

Biomerieux SA

14/08/2025 09:36

** RBC raises DiaSorin DIAS.MI to an "outperform" rating from "sector perform" saying the current valuation discount is a good buying opportunity in light of Italian medical diagnostics group's strong growth prospects

** The broker sees the key catalyst around Q4 results in March 2026, and highlights several other de-risking events in the meantime, including product launches and mid-term upside potential from its molecular diagnostic platform PLEX

** "We highlight now as good buying opportunity for a company with several attractive growth drivers to generate market-leading sales growth and double-digit EBITDA and earnings CAGRs over the mid-term," it said

** While DiaSorin shares have lost 17% YTD and trade at a 30% forward P/E discount compared to close peer BioMerieux BIOX.PA, the broker says the devaluation is not justified, given the company's solid H1 performance, limited impact from wider sector headwinds and attractive mid-term growth drivers

** DiaSorin shares were up 1.5% in early trade

 (Reporting by Gaia Neiman)

 ((Gaia.neiman@thomsonreuters.com))